Plasma Lipid Biomarker PCPro Associated with Shorter OS and Earlier Clinical Progression in Patients with Metastatic Hormone-Sensitive Prostate Cancer By Ogkologos - May 27, 2025 377 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a post-hoc analysis of the ENZAMET study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR A Lack of Resistance Gene Alterations in Baseline ctDNA Associated with... February 16, 2024 20 years on: how we’ve decreased cancer death rates December 17, 2022 EMA Recommends Granting a Conditional Marketing Authorisation for Odronextamab July 22, 2024 Cancer Patient Dresses Up To Cheer Others In Chemo & The... March 18, 2019 Load more HOT NEWS The Taylor Family Foundation gives £2.1m to support head and neck... Reducing Cancer’s Global Burden: A Conversation with NCI’s Dr. Satish Gopal Substantial Clinical Activity of Teclistamab in Patients with Heavily Pretreated Relapsed... ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk...
